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DOPAMINE AND ADDICTION: 
THE MEDIUM IS THE MESSAGE
Paul Cumming
A large variety of addictive substances and behaviors has been 
linked to changes in brain dopamine neurons, which are con-
nected to pathways intimately involved in motivation and re-
ward. Indeed, it has been claimed that all addictions, including 
nicotine, amphetamine, cocaine, alcohol, and perhaps gam-
bling converge on dopamine mechanisms in parts of the brain 
subserving reward or reinforcement. However, physiological 
studies suggest that this simple model may confuse the message 
(mediated by dopamine) that a reward has taken place, with the 
reward itself. Dopamine may in fact subserve the education of 
the brain to anticipate strategies for obtaining rewards in the 
future, but some drugs may hi-jack this normal motivational 
and adaptive process and become an end in themselves. Many 
addictive drugs produce short term changes in receptors for 
dopamine and other neurotransmitters. While these temporary 
changes may account for the unpleasant aspects of the acute 
phase of withdrawal, other factors must underlie craving and 
the risk of relapse in drug addiction. It is coming to be under-
stood that these long term changes are mediated by intracel-
lular proteins under the control of dopamine receptors, which 
ultimately serve to alter gene expression, thus inducing long-
lasting changes in neuronal activity. While many biochemical 
studies of addiction have been carried out in experimental ani-
mals, the advent of positron emission tomography (PET) has 
made possible the investigation of dopamine systems in living 
humans. Short term and chronic changes in brain dopamine 
have been noted in PET studies of nicotine, cocaine, alcohol 
and amphetamine addicts. It is hoped that a more complete 
biochemical understanding of the nature of addiction will ulti-
mately lead to improved treatments. 
»Addiction, like nostalgia in general, is a form of mourn-
ing, an attempt to keep the vanished love object close at 
hand…. And, like other forms of mourning, addiction 
keeps count.«
ANN MARLOWE, HOW TO STOP TIME
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An understanding of the relationship between brain dopamine and addiction 
has become well-established among the general public; It has been claimed 
in the popular press that one quarter of the adult population suffer from an 
obscure reward deficiency syndrome related to an inadequate dopamine 
system. The assumption is that this deficiency syndrome is symptomati-
cally alleviated by self-medication with a broad pharmacopoeia, including 
tobacco, alcohol, heroin, and by drug surrogates such as chocolate, jogging, 
shopping, or gambling. The implication is that brain dopamine is the route 
to all pleasures and the route to all vices. In an extreme form of this model, 
it has been assumed that the release of dopamine in the brain is synonymous 
with or identical to the reward itself. In other words, people are addicted to 
dopamine, and the diverse means for bringing about an increase in dopamine 
release in brain are simply different means to the same end. This notion 
seems reminiscent of the famous assertion of the Canadian media theorist 
Marshall McLuhan (1911-1980) that »the medium is the message«, by 
which he meant that the technical means of communication is somehow 
identical with the actual message. But what is dopamine, and what message 
does it normally transmit to the brain?
Dopamine is a small molecule derived from the essential amino acid 
tyrosine. In the blood, dopamine serves as a hormone regulating cardiovas-
cular tone, and it is the precursor for the adrenal hormones noradrenaline 
and adrenaline, which instruct the body to be prepared for »fight or flight«, 
by increasing cardiac output, and mobilizing sugar stored in the liver. But 
dopamine present in the blood cannot enter the brain. The production of 
dopamine in brain occurs within specific groups of brain cells (neurons) 
possessing the enzymes for synthesizing dopamine, storing it in synaptic 
vesicles and releasing the stored dopamine in a controlled manner. A large 
proportion of these dopamine cells is located in a region of the brain known 
as the mesencephalon, meaning the mid-brain. In post mortem specimens, 
the location of the dopamine cells can be discerned as a pair of black patches 
(the substantia nigra to early anatomists) the size of a small fingernail. The 
black color is due to the presence of neuromelanin, a byproduct of dopamine 
synthesis closely related to the skin pigment melanin. In the 1950s and 
1960s it was determined that the mesencephalic dopamine cells, number-
ing less than 500,000, give rise to fibers ascending to anterior parts of the 
brain, especially to a structure lying beneath the frontal cortex, known as the 
extended striatum. 
The human striatum, which is the size and shape of two side-by-side quail 
eggs, is composed of subdivisions known as the putamen, the caudate, and 
the nucleus accumbens. Each of these three divisions contains other brain 
cells that are endowed with dopamine receptors, making them responsive 
to dopamine released in their vicinity. The three anatomical divisions of the 
striatum all receive similar dopamine inputs, but are distinguished by the 
parts of cerebral cortex with which they are integrated or connected. Specifi-
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cally, the putamen is linked to the motor and sensory cortex, the caudate is 
linked to parts of the cortex involved in cognition and sensory integration, 
while the nucleus accumbens is most linked to the limbic cortex, which is 
involved in motivation. So, dopamine cannot be said to have a single uni-
tary function. Rather, dopamine does something that depends on the type of 
cerebral cortex involved.
What then is it that dopamine does, once released in the striatum? It is 
now understood that dopamine communicates with striatal neurons via 
several types of dopamine receptors. Activation by dopamine alters the elec-
trical activity of those striatal neurons bearing dopamine receptors. These 
cells in turn project to other neurons ultimately feeding back to the cerebral 
cortex, which, itself innervates the striatum. As such, dopamine is just one 
player in a loop-like circuit of neurons, the purpose of which seems to be to 
modulate its own activity in a controlled manner, imparting a sort of plastic-
ity allowing the brain to learn or adapt to new circumstances. However the 
role of dopamine in brain function was first understood by exclusion, by 
observing what happens in the absence of dopamine. The loss of melanin-
pigmented dopamine neurons in brain of patients dying with Parkinson’s 
disease was described in the 1950s, leading in the 1960s to the rationale use 
of levodopa for the alleviation of disease symptoms. A notable symptom 
of Parkinson’s disease is rigidity of the skeletal muscles, suggesting that 
dopamine is a facilitator of normal movement. More properly, it might be 
said that dopamine mediates the correct response to sensory feed-back from 
the muscles and tendons such that movement is achieved by modulation of 
a baseline muscle tone. 
Modern imaging studies with positron emission tomography (PET) indi-
cate that the dopamine deficiency of Parkinson’s disease is greatest in the 
putamen, which is linked to the motor and sensory pathways. 
In the very early 1970s, it was discovered that rats were motivated to 
receive pulses of electrical stimulation via an electrode directed towards the 
dopamine fibers ascending en route to the striatum (Breese et al., 1971). 
Rats could be trained to press a lever hundreds of times for a single pulse 
of electricity, and, famously, would continue pressing a lever for electrical 
»reward« to the exclusion of all other activities. Around the same time it was 
noted that rats would continue to press a lever for small intravenous injec-
tions of cocaine, only so long as the dopamine innervation of the nucleus 
accumbens was intact (Roberts et al., 1977). While the behavioral stimulant 
effect of cocaine is unaffected by lesions to the nucleus accumbens, the 
motivation to take cocaine is gone; the salt has lost its savor. Together, these 
findings in rats helped provide the basis for the linkage between dopamine 
release in the nucleus accumbens of the ventral striatum and the rewarding 
and motivational aspects of stimulant drugs, as distinct from their behavioral 
effects, which are mediated by the motor systems of the dorsal striatum.
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During the early 1980s, the cerebral microdialysis technique became 
available for studies of dopamine release evoked by psychostimulant drugs. 
In this technique, the extracellular milieu is sampled through a small porous 
plastic fiber, and the concentration of dopamine and its metabolites in the 
fluid of the brain can be measured during treatment with psychoactive com-
pounds. The preferential release of dopamine in the rat nucleus accumbens 
by amphetamine was an early finding using this technique (Hernandez et al., 
1987). The list of drugs with abuse potential for humans and which increase 
dopamine release in the nucleus accumbens of rats now includes nicotine, 
amphetamine, cocaine, and ethanol (di Chiara and Imperato, 1988). Natu-
ral reinforcers such as food likewise evoke a dopamine release in the rat 
nucleus accumbens. Thus, there seemed to be a clear association between 
dopamine release, obtained by any number of means, and the experience 
of positive motivation, commonly known as reward. In a simple interpreta-
tion of this finding, dopamine release came to be identified with the reward 
itself (the medium is the message). However, this identification failed to 
clarify the nature of addiction, since it did not explain why certain drugs, 
with repeated use, establish themselves as primary motivators, whereas food 
intake, for example, is maintained within reasonable limits for most of us. 
Starving people may commit crimes to obtain food, but well-fed people 
seldom commit crimes to satisfy a craving for sugar.
The biochemical factors underlying addiction are only now coming to be 
understood. In the first instance, pharmacologists consider that addiction is 
based upon a form of habituation, where the nervous system has become 
accustomed to an excess of some pharmaceutical. The physiological mani-
festations of this process have been linked to changes in neuroreceptors. 
Hence, repeated exposure to nicotine results in inactivation of nicotinic re-
ceptors in brain of experimental animals (Ochoa et al., 1990), chronic mor-
phine treatment decreases the abundance of opioid receptors (Turchan et al., 
1999) and chronic methamphetamine treatment decreases the abundance of 
dopamine receptors (McCabe et al. 1987), which are indirectly activated by 
amphetamine-evoked dopamine release. These and other neurotransmitter 
systems interact in complex manners; Thus, repeated nicotine treatment 
inactivates dopamine receptors in rodent brain (Janson et al., 1992), an ef-
fect presumably mediated by the ability of nicotine to activate dopamine 
release above normal levels. These sorts of changes doubtless contribute to 
the phenomenon of tolerance, whereby habitual drugs users can consume 
quantities which might be fatal to inexperienced users. Furthermore, sud-
den cessation of the drug of choice leaves the brain and peripheral tissues 
bereft of adequate activation of these receptors, which results in the acute 
syndrome of withdrawal. It is this withdrawal which the drug user seeks to 
avoid; Withdrawal from opiates can evoke criminal or reckless behavior on 
the part of the unfortunate addict.
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However, it is far from certain that the changes in receptor density noted 
above are irreversible. For example, withdrawal from methamphetamine 
during several weeks resulted in normalization of the dopamine markers in 
brain of rats which had become accustomed to self-administer the drug (Ste-
fanski et al., 2002). Nonetheless, craving and the risk of relapse can persist 
for many years in abstinent drug users. Additional factors, down-stream to 
the receptors themselves must account for the persistent risk of relapse. In 
order to understand the long-term consequences of drug addiction, it must 
be considered that dopamine receptors are merely switches for informing 
a cell bearing the receptors that a signal has arrived. When dopamine, for 
example, binds to its receptors in brain, its signal is transferred to the cell 
bearing those receptors by specific proteins which become activated by the 
binding of dopamine. In many neuroreceptors, the binding of the natural 
transmitter initiates a chain of events freeing into the cellular milieu a class 
of proteins characterized by their ability to bind the nucleotide GTP, a small 
molecule related to a basic chemical component of DNA. These proteins 
are collectively known as GTP-binding proteins, more frequently referred 
to as G-proteins. When released into the cell, the G-proteins in turn alter the 
activity of specific enzymes, which can influence the rate of generation of 
another small molecule, known as cyclic-AMP, which in turn binds to still 
other enzymes, altering their activities. Thus, if dopamine is the first mes-
senger, the G-proteins liberated by activated dopamine receptors are known 
as second messengers. They activate a process known as a »signal transduc-
tion cascade«, in which many diverse molecular targets can be activated or 
inactivated, all under the regulation of dopamine receptors. Sometimes mul-
tiple neuroreceptor types converge on the same second messenger systems, 
such that the full complexity of the possible outcomes of receptor activation 
can be very complex indeed.
Activation of neuroreceptors by their neurotransmitters is necessary but 
not sufficient to initiate signaling within the cells bearing the receptors. 
Any process interfering in the abundance of the G-proteins, or their ability 
to interact with their preferred receptors, can alter the signaling in brain. 
Chemical destruction of G-proteins attenuates the reinforcing properties of 
both cocaine and heroin (Self et al., 1994), indicating that these two very 
different classes of drugs converge on common second messenger systems. 
Chronic exposure to morphine alters the properties of G-proteins in the 
noradrenaline-rich part of the brain of rats (Nestler et al., 1989), such that 
the responsiveness of these neurons is fundamentally altered. Part of the 
syndrome of opiate withdrawal, especially the anxiety, may be related to 
misregulation of the noradrenaline neurons via this mechanism. However, 
in order to elucidate the biochemical changes underlying long-lasting risk 
for relapse behavior, one must probe deeper still, and consider the way in 
which paths can be burned into the nervous system. Here we invoke what 
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has been called the terniary messengers, i.e. the proteins which are respon-
sive to modulation by the secondary messenger. 
If neurotransmitters such as dopamine modulate the G-proteins, which 
in turn regulate the activity of enzymes generating cyclic-AMP, what are 
the subsequent steps in signal transduction? Fifteen years ago it came to be 
appreciated that cyclic-AMP exerts a powerful regulation of other enzymes, 
known as protein-kinases, which serve to transfer a phosphate chemical 
group, very close in nature to the phosphoric acid which is so detrimental 
to the dental health of Coca-Cola addicts. The targets of the protein-kinase 
reaction are other proteins, collectively known as phosphoproteins. Proteins 
in general are large molecules, often containing hundreds of the amino acid 
building blocks. But incorporation of a single phosphate group into a phos-
phoprotein can fundamentally alter its properties, resulting in a profound 
alteration of the life of the cell. Therefore it is a matter of great interest 
that morphine acts by inducing, via cyclic-AMP-regulated enzymes, the 
tagging of intracellular proteins by phosphate (Guitart and Nestler, 1989). 
Among the diverse proteins modulated by these pathways is known as the 
cyclic-AMP response element binding protein (CREB), which has been 
implicated in the propensity to consume excessive amounts of alcohol 
(Pandey et al., 2004). CREB belongs to the family of transcription factors, 
which ultimately serve to signal the original neurotransmitter message to the 
cell nucleus, wherein the DNA, containing the entire genetic code resides. 
CREB and other transcription factors bind to DNA in such as way as to 
alter the expression of specific genes, which in turn can produce structural 
and physiological changes in the cell. CREB and other transcription factors 
can be modulated by cocaine (BT Hope, 1998), and nicotine (Pluzarev and 
Pandey, 2004); It is precisely this level of altered cellular behavior which 
is now thought to underlie the long lasting detrimental effects of addictive 
drugs. By changing gene expression, amphetamine, morphine and other ad-
dictive drugs may teach the brain a lesson it cannot forget, to the detriment 
of the owner of the brain in question. 
Positron emission tomography (PET) is a relatively new tool for investi-
gating the status of neurotransmitter systems in brain of living humans and 
experimental animals. Radiopharmaceuticals for PET are prepared on-site 
using a particle accelerator known as a cyclotron, a requirement imposed 
by the very short half-life (2-120 minutes) of the isotopes for PET studies. 
Upon injection of the radiopharmaceutical into the patient’s blood, usually 
via an arm vein, it passes into the brain, and may accumulate in specific brain 
regions richly endowed with binding sites for the radiopharmaceutical in 
question. There, the radioactive atom ultimately decays, releasing a positron, 
which is the name for an anti-matter partner of an ordinary electron. After 
traveling some millimeters in the medium of the brain, the positron meets 
an electron head-on, and the two particles annihilate each other, releasing 
their entire energy (E=mc2, in the famous formulation of Einstein) as two 
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very high energy photons known as gamma-rays. The two gamma-rays fly 
away from each other at the speed of light, but may encounter gamma-de-
tectors, if the annihilation took place while the patient’s head was inside a 
PET scanner. If the PET, which actually consists of rings of many hundreds 
of small detectors, counts two events, that is the arrival of two gamma-rays, 
simultaneously in the interval of one millionth of a second, it is registered 
that a radioactive decay had taken place at a point half-way between the 
two detector elements. Counting many million of these events, in conjunc-
tion with high-speed computers, allows the calculation of a picture or map, 
showing the distribution of radioactivity in the head as a function of time.
Unfortunately, PET has not yet proven useful for the study of second 
messenger systems or transcription factors, but has been mainly used for 
the study of changes in the number of neuroreceptors associated with drug 
addiction. In recent decades, PET has provided considerable evidence that 
dopamine is a key player in the unconditioned properties of many drugs 
with abuse potential. Dopamine receptors in human brain can be visual-
ized and quantified in PET studies employing a radioactive drug such as 
[11C]-raclopride, which binds to specific dopamine receptors in brain. Using 
this method, the abundance of dopamine receptors has been shown to be 
reduced in brain of living alcoholics (Volkow et al., 1996), and in patients 
suffering from cocaine dependence (Martinez et al., 2004). These findings 
are generally consistent that a wide array of addiction disorders are associ-
ated with changes in the availability of dopamine receptors.
The number of available dopamine receptors that can be detected during 
a particular PET scanning session is reduced by simple competition from 
brain dopamine for binding to the same sites. Consequently, pharmacologi-
cal challenges or cognitive tasks altering dopamine release alter the PET 
signal. In [11C]-raclopride-PET studies, smoking evokes a decline in [11C]-
raclopride binding, indicative of dopamine release of comparable magni-
tude to that evoked by amphetamine (Brody et al., 2004), cocaine, and other 
psychostimulants. Furthermore, the magnitude of the change in PET signal 
in the nucleus accumbens evoked by smoking correlates positively with 
the hedonic value experienced by individual smokers (Barrett et al., 2004). 
These findings with smoking, and comparable PET studies with cocaine and 
amphetamine, lend further support to the linkage between dopamine and 
rewarding properties of drugs of abuse. In some PET studies, natural rein-
forcers such as palatable food, have been also shown to evoked dopamine 
release in the nucleus accumbens, but the magnitude of the changes is gen-
erally less than that evoked by addictive drugs (Small et al., 2003). However, 
it is notable that the individual magnitude of these effects is greater in the 
pathologically obese (Wang et al., 2002), suggesting that the conditioned 
properties of palatable food may be greater in those with eating disorders, 
either due to a pre-existing condition, or reflecting a kind of over-learned 
association between food and reward.
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A very high dose of nicotine is required to evoke a discernible decline in 
[11C]-raclopride binding in striatum of living anesthetized pigs (Cumming 
et al., 2003), although smoking a single cigarette was sufficient to evoke 
a substantial decline in [11C]raclopride binding in the human PET studies 
cited above. Thus, the effects of smoking on [11C]-raclopride binding must 
be mediated by additional factors such as conditioning or expectation, or 
alternately by the complex pharmacology of tobacco smoke. The former 
possibility, that of cognitive modulation of the response to stimulant drugs, 
is supported by other PET studies in which an inert placebo could evoke an 
»amphetamine-like« decline in [11C]-raclopride binding (de la Fuente-Fern-
andez et al., 2002). It is the experience of many drug addicts that exposure 
to an environment formerly associated with drug taking, is the most power-
ful evoker of craving. Ask any reformed smoker in a smoky bar! Recent 
pharmacological studies lend further support to this obvious relationship 
between environmental craving and environmental cues. In some sense, the 
cues evoke a memory of the addict’s condition just prior to their last use of 
their drug. The nervous system remembers well what to do next, accounting 
for the great risk of relapse among addicts. 
The lack of simple correspondence between PET results and conventional 
pharmacology, especially perhaps in the case of tobacco addiction, makes 
impossible the equating of dopamine and reward. Indeed, current thinking 
about the nature of tobacco addiction entails complex arguments about 
conditioned aspects of smoking behavior, in conjunction with sensitization 
of smoking-evoked dopamine release, such that the behavior eventually 
becomes self-supporting, irrespective of its primary rewarding properties 
(Balfour, 2004).
Dopamine in the motor striatum allows the correct modulation of mus-
cle tone required for voluntary movement; its absence underlies the motor 
symptoms of Parkinson’s disease. What analogous process could dopamine 
mediate in the nucleus accumbens, which differs from the motor striatum 
mainly with respect to its connectivity with limbic or emotion-related re-
gions of the brain rather than the parts of the cerebral cortex which control 
the skeletal muscles? The simple relationship between dopamine in the 
nucleus accumbens and the experience of reward has been challenged on 
the basis of key experiments in awake, non-human primates. Researchers 
have recorded the electrical activity of dopamine cells projecting to the 
nucleus accumbens of monkeys performing behavioral tasks. Specifically, 
the monkeys were trained to associate a tone of sound with a squirt of fruit 
juice, which they find very rewarding. If dopamine release were synony-
mous with reward, the dopamine cells should have been active immediately 
following the juice administration. However, this was not the case. Instead, 
the electrical activity of the monkey dopamine neurons projecting to the 
nucleus accumbens increased only when an unexpected reward took place, 
not preceded by the usual musical tone (Schultz et al., 1977). 
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The findings of Schultz et al. could be interpreted to mean that dopamine 
activity in the nucleus accumbens informs the rest of the brain that a sur-
prise reward has taken place, such that adaptive learning can occur so as 
to increase the likelihood of these rewards occurring in the future. In other 
words, dopamine instructs the nucleus accumbens to take note of what the 
rest of the brain was doing at the time of an unexpected reward, allowing 
for optimization of the attainment of future rewards. In the context of the 
motor system, dopamine may likewise inform the brain that there has been 
a disagreement between the command sent to the skeletal muscles and the 
consequent motor response. In Parkinson’s disease, this optimization can 
no longer take place, resulting in rigid paralysis. In an extension of the 
Schultz model of dopamine and reward, addiction has been described as a 
»non- compensatable change in a temporal-difference reinforcement learn-
ing« algorithm (AD Redish, 2004). Here, cocaine, amphetamine, nicotine 
and other addictive substances hijack the mechanism for adjusting behavior 
in response to unexpected natural rewards, and focuses our learning and 
adaptive mechanisms on the behavior just preceding the non-compensatable 
stimulus, i.e. smoking or other drug-taking.  
The truth about addiction must be related to the nature of the salience 
of natural rewards. We are not wired in a simple manner such that a deci-
sion to act or the evaluation of the consequences of our actions is based 
upon an accumulation of poker chips, or »reward units«. Rather, the poker 
chips, which may be measured in the units of dopamine release, convey the 
element of surprise when one experiences an unexpected reward. Addic-
tive drugs erode normal motivational state by supplanting the message by 
the medium, which is the physiological mechanism for announcing that a 
reward has taken place. This conception will require a radical rethinking of 
the relationship between dopamine and addiction, and may serve to explain 
why associative factors such as cueing to environmental stimuli are key 
factors in evoking relapse for drug-taking; a smoky bar is the worst environ-
ment for a reformed smoker or alcoholic. Sigmund Freud, who attempted 
to treat morphine addiction with cocaine, famously discovered the failure of 
dopamine-activating drugs for the treatment of addiction. Future therapies 
will be designed to break the association between dopamine release and 
conditioned reward, which is the hallmark of addiction. 
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